Abstracts tagged "Muckle-Wells syndrome and interleukins (IL)"

Abstract Number: 748 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients with Cryopyrin Associated Periodic Syndrome: Results From Meta-Analysis of 5 Studies
Helen J. Lachmann¹, Jasmin B. Kuemmerle-Deschner², Toshio Heike³, Toshiro Hara⁴, Shumpei Yokota⁵, Phil Mckernan⁶, Albert Widmer⁶, Nicole Davis⁷ and Eric Hachulla⁸, ¹UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ²University Hospital Tuebingen, Tuebingen, Germany, ³Department of Pediatrics, Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Pediatrics, Department of Pediatrics, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan, ⁵Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Japan, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Department of Internal Medicine, Claude Huriez University Hospital, Lille, France
Background/Purpose: Canakinumab (CAN) is approved in over 60 countries for the treatment of CAPS. This meta-analysis evaluated the efficacy and safety of CAN and assessed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].